4.3 Nonadherence, Affordability Barriers & Gaps in Therapy

Nonadherence, Affordability Barriers & Gaps in Therapy

Quick Answer: Nonadherence means the patient is not taking therapy as intended. Affordability barriers are cost-driven reasons for that behavior. Gaps in therapy are missing indicated medications. Technicians detect all three through claims patterns, patient interview, and condition-to-list comparison—then flag them for pharmacist action.

These three problems dominate everyday MTM screening. They are related but not identical. A patient may be fully adherent to an incomplete regimen (gap without nonadherence), or nonadherent because of cost (adherence + affordability), or missing fills because of side effects (adherence secondary to safety).

---

Nonadherence: Patterns Technicians Can See

Primary vs secondary nonadherence

• Primary nonadherence: The prescription is written but the patient never fills or picks it up.
• Secondary nonadherence: The patient starts therapy but misses doses, delays refills, or stops early.

Claims systems catch secondary patterns more easily (late refill cycles). Primary nonadherence may appear as an e-prescription that never became a sold claim—worth checking when a CMR patient says, "I never got that new cholesterol medicine."

Refill timing and therapy lapses

A therapy lapse is a stretch of days without coverage—missed fills, long gaps between fills, or abandoned chronic therapy. Example: a 30-day antihypertensive last filled 55 days ago with no delivery on file. That is not a subtle signal; it is a red flag for uncontrolled blood pressure risk and Star Ratings adherence impact on RAS antagonists when applicable.

Disease-specific adherence clues

COPD/asthma example: frequent albuterol (SABA) refills with rare tiotropium (LAMA) or other controller refills suggest overreliance on rescue therapy because controller therapy is underused. That is an adherence (and possibly technique/education) problem, not "evidence of complete adherence."

Detailed PDC math belongs in the adherence-calculations chapter. Here, know the qualitative idea: repeated short coverage relative to the measurement window signals nonadherence risk, and PQA commonly treats PDC ≥ 80% as adherent for Star Ratings classes.

---

Affordability Barriers

Cost is repeatedly listed among the top adherence barriers alongside regimen complexity, side effects, forgetfulness, and health literacy. Affordability problems sound like:

• "I stretch the bottle."
• "I only take it every other day."
• "I can't afford the brand one."
• "I choose food over the copay this month."

Classify cost rationing as an adherence MRP due to affordability, not as proof the drug is unnecessary. Especially escalate when the drug is high-risk if underdosed (anticoagulants, insulin, transplant immunosuppressants, seizure medicines).

What technicians can do (within scope)

• Document the exact cost barrier and which drug is affected.
• Ask whether the patient has tried the pharmacy's discount programs, 90-day mail, or patient-assistance pathways as offerings your site already uses—without promising coverage.
• Alert the pharmacist to consider therapeutic interchange, lower-cost alternatives, or manufacturer/assistance options when clinically appropriate.
• Support medication synchronization, adherence packaging, and 90-day fills when the pharmacist/program offers them as adherence interventions.

What technicians must not do

• Independently switch the patient to a different drug class to save money.
• Advise tablet splitting unless the pharmacist and product labeling support it.
• Shame the patient—motivational, respectful language keeps the conversation open.

Scenario — Affordability on Anticoagulant Therapy

Patient: "My brand blood thinner is $80 a month. I skip days so it lasts." Tech documentation: Adherence problem due to affordability; patient omitting doses of anticoagulant; requests pharmacist review for cost-saving options and safety counseling. Why urgency is high: Under-anticoagulation raises clot/stroke risk; this is not a "wait for annual CMR paperwork" issue.

---

Gaps in Therapy (Untreated Indications)

A gap in therapy means indicated treatment is absent. You often find gaps by comparing:

1. Documented conditions (diabetes, ASCVD, heart failure, osteoporosis, etc.)
2. Immunization and preventive care status when in scope
3. The current medication list and recent claims

Classic gap examples

• Age 40–75 with diabetes (or any patient with established ASCVD) not on a statin → untreated indication / needs additional therapy.
• Patient with diabetes and A1C 9.2% on metformin alone → effectiveness problem that often includes needs additional therapy after pharmacist assessment.
• Missing controller inhaler in persistent asthma/COPD when history supports it.
• Preventive gaps technicians may surface for pharmacist/clinic follow-up (for example, age-based vaccines or screenings your workflow tracks)—distinct from drug MRPs but related "care gap" thinking.

Gaps differ from nonadherence: there may be no late fill because there was never a therapy to fill. If you only watch refill queues, you will miss gaps.

---

Barriers Interview: Find the "Why"

Missed fills are symptoms. Ask why:

• Cost / insurance — copay, deductible, coverage gap, prior authorization delays
• Complexity — multiple dosing times, many bottles, confusing inhalers
• Side effects — cough, nausea, muscle pain, sexual side effects
• Forgetfulness — no routine, cognitive impairment, no pill organizer
• Beliefs / literacy — "I feel fine so I don't need it," unclear purpose
• Access — transportation, pharmacy hours, caregiver gaps

Open questions beat yes/no checkboxes: "What gets in the way of taking your evening pills?" invites richer answers than "Do you take your medicine?"

Scenario — Controller vs Rescue Pattern

Claims show albuterol filled monthly; tiotropium last filled four months ago. Tech flag: Possible controller nonadherence with rescue overuse in COPD; request pharmacist counseling on maintenance inhaler use and technique. Not the correct interpretation: "Patient is fully adherent because they pick up something every month."

---

Linking Findings to MTM Outputs

• MAP actions for adherence/affordability might include: "Use the weekly pill box every Sunday," "Call us before you skip a blood thinner dose," "Ask about 90-day supply at your next pickup."
• Pharmacist interventions may include prescriber consults for indicated therapy (statin start), regimen simplification, or prior authorization support.
• Follow-up 1–2 weeks after an adherence-focused CMR is appropriate to see whether the plan started.

Technician Closing Checklist

1. Did I capture what is missing or late?
2. Did I capture why (cost, side effect, forgetfulness, access)?
3. Did I mark urgency for high-risk drugs?
4. Did I avoid giving unauthorized clinical fixes?
5. Did I place the flag where the pharmacist will see it before the patient leaves or before the next fill?

Nonadherence, affordability, and therapy gaps are where technicians create outsized value: you connect claims data and human stories so pharmacists can repair the regimen before labs worsen, hospitalizations happen, or quality measures fail.